LB Pharmaceuticals Inc filed a Form 8-K on September 3, 2026, disclosing the appointment of Joseph M. Miller as Chief Financial Officer, effective September 2, 2026.

Key Highlights

  • New CFO appointed: Joseph M. Miller, age 52, was appointed Chief Financial Officer of LB Pharmaceuticals Inc, effective September 2, 2026.
  • Base salary: Mr. Miller is entitled to an initial annual base salary of $530,000.
  • Annual bonus target: Mr. Miller's target annual discretionary bonus is 40% of his annual base salary.
  • Stock option grant: Subject to Board approval, Mr. Miller will receive an option to purchase 200,000 shares of common stock, vesting over four years.
  • Prior role: Mr. Miller most recently served as CFO of Aurinia Pharmaceuticals Inc. from April 2020 to March 2026.
  • Change-of-control severance: In a qualifying termination tied to a change of control, Mr. Miller would receive a lump sum equal to one year of base salary plus 150% of his target bonus, among other benefits.

LB Pharmaceuticals CFO Appointment: Compensation and Severance Terms

According to the filing, LB Pharmaceuticals Inc (NASDAQ:LBRX) announced that Joseph M. Miller has joined the company as Chief Financial Officer with an effective date of September 2, 2026. The company disclosed that Mr. Miller, age 52, has over two decades of experience in public and private biotech and commercial stage companies across the health sciences, biotech, and pharmaceutical sectors. Before joining LB Pharmaceuticals, he served as CFO of Aurinia Pharmaceuticals Inc. from April 2020 to March 2026. Prior roles noted in the filing include CFO, Principal Executive Officer, and Corporate Secretary at Avalo Therapeutics Inc. (formerly Cerecor, Inc.), Vice President of Finance at Sucampo Pharmaceuticals, Inc., and various finance and management positions at QIAGEN N.V. and Eppendorf AG. Mr. Miller began his career in the audit practice of KPMG LLP and holds a B.S. in accounting from Villanova University. He is a Certified Public Accountant.

The filing states that under Mr. Miller's employment agreement, his employment is "at will" and continues until terminated by either party. He is entitled to participate in employee benefit plans generally available to the company's employees and is subject to confidentiality covenants and a non-solicitation covenant for 12 months following any termination. The option to purchase 200,000 shares will vest with 25% on the first anniversary of the Start Date and the remainder monthly thereafter, subject to continued service. The option is described as an inducement grant under Nasdaq Listing Rule 5635(c)(4).

On severance, the filing details two scenarios. In a qualifying termination within three months before or 12 months after a change of control, Mr. Miller would receive a lump sum equal to one year of his then-current annual base salary plus 150% of his target bonus, COBRA premium reimbursement for up to 12 months, and acceleration of all unvested equity awards. Outside a change-of-control period, a qualifying termination would entitle him to nine months of base salary paid as salary continuation and COBRA reimbursement for up to nine months. The filing also notes the company will enter into its standard indemnification agreement with Mr. Miller.

What Was Disclosed

LB Pharmaceuticals Inc disclosed the appointment of Joseph M. Miller as CFO effective September 2, 2026, along with the key terms of his employment agreement, including base salary, bonus target, equity grant, and severance arrangements under various termination scenarios.